Live
- GMR Airports Unveils AI-Powered Digital Twin Platform to Transform Airport Operations
- India poised to become leading maritime player: PM Modi
- Top Causes of Kidney Stones and How to Recognize Silent Symptoms
- India’s renewable energy capacity logs 14.2 pc growth at 213.7 GW
- Winter Session of Odisha Assembly adjourned sine die
- Biden calls Trump's tariff approach 'major mistake'
- After Drama Over Eknath Shinde’s Chief Minister Race, Maharashtra Cabinet Formation Faces New Tensions
- Egyptian FM, Blinken discuss recent developments in Syria
- Iran's supreme leader says Syria's developments result of US-Israeli 'plot'
- Elon Musk to Purchase $100 Million Luxury Mansion Next to Donald Trump's Mar-a-Lago, Report Reveals
Pfizer to seek emergency approval for vaccine
Pfizer to seek emergency approval for vaccine
Pfizer on Friday announced that it is moving ahead with its request of asking the US regulators to allow emergency use of its Covid-19 vaccine, which has shown 95 per cent efficacy in a totality of two data sets released in the last 10 days.
New York: Pfizer on Friday announced that it is moving ahead with its request of asking the US regulators to allow emergency use of its Covid-19 vaccine, which has shown 95 per cent efficacy in a totality of two data sets released in the last 10 days.
Unless some nasty surprises turn up, Pfizer's action on Friday could be the first step towards vaccinating the most vulnerable Americans by December end.
Pfizer and another US company, Moderna, have broken all vaccine development speed records in their race for a cure over the last nine months.
US regulators are standing by for the approval process while coronavirus cases are surging to record levels across all the 50 states.
The Vaccines and Related Biological Products Advisory Committee in the US Food and Drug Administration is a key player in how this process rolls along.
Pfizer's submission also includes safety data on approximately 100 children aged 12-15 years.
"Our work to deliver a safe and effective vaccine has never been more urgent," Pfizer CEO Albert Bourla said in a statement.
Pfizer and BioNTech expect to produce a total of 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. US regulators hope to have 20 million vaccine doses each from Moderna and Pfizer available for distribution in late December.
